Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 11/20 | 0.57 |
| ▸ | HTR2C | P28335 | 11/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569396 | 0.88 | MCHR1 (0.66) | MCHR1HRH3HTR2AHTR2CLTA4H | |
| SCHEMBL5565308 | 0.86 | LTA4H (0.74) | MCHR1HRH3LTA4H | |
| SCHEMBL5568518 | 0.86 | SRC (0.62) | MCHR1HRH3HTR2AHTR2CLTA4H | |
| SCHEMBL5943709 | 0.79 | KDR (0.62) | MCHR1HRH3HTR2AHTR2CLTA4H | |
| SCHEMBL5621111 | 0.76 | HRH3 (0.60) | MCHR1HRH3LTA4H | |
| SCHEMBL5564591 | 0.76 | MCHR1 (0.67) | MCHR1HTR2AHTR2CKDR | |
| SCHEMBL14022013 | 0.76 | EPHX1 (0.63) | KDR | |
| SCHEMBL5621809 | 0.75 | MCHR1 (0.61) | MCHR1HTR2AHTR2CKDR | |
| SCHEMBL27720109 | 0.75 | MAPK14 (0.52) | MCHR1HRH3HTR2AHTR2CKDR | |
| SCHEMBL5569661 | 0.75 | GSK3B (0.60) | MCHR1HRH3HTR2AHTR2CKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007519653-A | — | — | 2007-07-19 | — | — | JP | claimed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | claimed |
| EP-1730111-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-12-13 | — | — | EP | claimed |
| WO-2005075425-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | WO | claimed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| EP-1730111-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005075425-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | MCHR1 4656/4885HRH3 2940/4885HTR2A 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.